Univ Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, F-35000, Rennes, France.
Kereval, F-35235, Thorigné-Fouillard, France.
Stud Health Technol Inform. 2024 Aug 22;316:1373-1377. doi: 10.3233/SHTI240667.
The ONCO-FAIR project's initial experimentation aims to enhance data interoperability in oncology chemotherapy treatments, adhering to the FAIR principles. This study focuses on integrating the HL7 FHIR standard to address interoperability challenges within chemotherapy data exchange. Collaborating with healthcare institutions in Rennes, the research team assessed the limitations of current standards such as PN13, mCODE, and OSIRIS, leading to the customization of twelve FHIR resources complemented by two chemotherapy-specific extensions. The methodological approach follows the Integrating the Healthcare Enterprise (IHE) framework, organizing the process into four key stages to ensure the effectiveness and relevance of health data reuse for research. This framework facilitated the identification of chemotherapy-specific needs, the evaluation of existing standards, and data modeling through a FHIR implementation guide. The article underscores the importance of upstream interoperability for aligning chemotherapy software with clinical data warehouse infrastructure, showcasing the proposed solution's capability to overcome interoperability barriers and promote data reuse in line with FAIR principles. Furthermore, it discusses future directions, including extending this approach to other oncology data categories and enhancing downstream interoperability with health data sharing platforms.
ONCO-FAIR 项目的初步实验旨在通过 FAIR 原则提高肿瘤化疗治疗中的数据互操作性。本研究侧重于整合 HL7 FHIR 标准，以解决化疗数据交换中的互操作性挑战。研究团队与雷恩的医疗机构合作，评估了当前标准（如 PN13、mCODE 和 OSIRIS）的局限性，从而定制了十二个 FHIR 资源，并补充了两个化疗专用扩展。该方法遵循集成医疗企业 (IHE) 框架，将该过程组织成四个关键阶段，以确保健康数据再用于研究的有效性和相关性。该框架通过 FHIR 实施指南，促进了对化疗专用需求的识别、现有标准的评估和数据建模。本文强调了为使化疗软件与临床数据仓库基础设施保持一致而进行上游互操作性的重要性，展示了所提出解决方案克服互操作性障碍并根据 FAIR 原则促进数据重用的能力。此外，它还讨论了未来的方向，包括将这种方法扩展到其他肿瘤学数据类别，并增强与健康数据共享平台的下游互操作性。
